<DOC>
	<DOCNO>NCT02597114</DOCNO>
	<brief_summary>AGT-181 fusion protein contain alpha-L-Iduronidase intend deliver enzyme peripherally brain , administer intravenously . This study extension safety dose range study obtain long term safety exposure data , well information biological activity investigational drug</brief_summary>
	<brief_title>Extension Study AGT-181-102 Evaluate Long Term Safety Activity AGT-181</brief_title>
	<detailed_description />
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis I</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Must complete clinical trial AGT181102 Voluntary write consent patient legally responsible representative All woman childbearing potential sexually mature male must advise use medically accept method contraception throughout study . Negative pregnancy test ( female ) Refusal complete screening evaluation . Any medical condition circumstance may significantly interfere study compliance Patient pregnant lactate Clinically significant spinal cord compression , evidence cervical instability . Subject develop clinically relevant hypersensitivity AGT181</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>